KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Smith & Wesson Brands (SWBI) Cash & Equivalents (2016 - 2026)

Smith & Wesson Brands (SWBI) has disclosed Cash & Equivalents for 17 consecutive years, with $18.4 million as the latest value for Q1 2026.

  • Quarterly Cash & Equivalents fell 31.02% to $18.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.4 million through Jan 2026, down 31.02% year-over-year, with the annual reading at $25.2 million for FY2025, 58.53% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $18.4 million at Smith & Wesson Brands, down from $22.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $120.7 million in Q2 2022, with the low at $18.0 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $51.3 million, with a median of $44.2 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 79.75% in 2022, while the deepest fall reached 73.04% in 2022.
  • Over 5 years, Cash & Equivalents stood at $43.0 million in 2022, then grew by 2.83% to $44.2 million in 2023, then dropped by 11.54% to $39.1 million in 2024, then tumbled by 42.62% to $22.4 million in 2025, then dropped by 17.88% to $18.4 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $18.4 million, $22.4 million, and $18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.